FINWIRES · TerminalLIVE
FINWIRES

US FDA Clears Phase 3b Study of Caliway Biopharma's CBL-514 Fat-Reduction Drug

By

Caliway Biopharmaceuticals (TPE:6919) said the US Food and Drug Administration has allowed its investigational new drug application for CBL-0303, a Phase 3b long-term follow-up study of CBL-514 for reducing abdominal subcutaneous fat, to proceed after the 30-day review period.

The study in the U.S. is expected to enroll about 300 participants who completed the company's pivotal Phase 3 trials to evaluate the long-term safety and durability of CBL-514's efficacy.

It will assess the drug's long-term safety and whether its effectiveness in reducing abdominal subcutaneous fat is maintained over time, with eligible participants also able to receive re-treatment.

Related Articles

Asia

Frasers Centrepoint Trust Renews Property Management Agreements

Frasers Centrepoint Trust (SGX:J69U) renewed five-year property management agreements for four Singapore malls till 3031, according to a Friday filing with the Singapore Exchange.Fee structures for three of the properties are set at 2% of gross revenue plus 2% of net property income annually, along with an additional 0.5% NPI fee, which will cover leasing commissions.For the fourth property, the Waterway Point, the structure is based on 2% of gross revenue and 2.5% of NPI without a separate leasing commission structure.

SGX:J69U
Asia

CATL to Invest in New Zealand Developer of Battery-Grade Graphite from Wood

Contemporary Amperex Technology (SHE:300750, HKG:3750) will invest in New Zealand-based CarbonScape, a company that converts wood to graphite for use in lithium batteries, according to a Monday press release.The world's largest battery maker and Hong Kong-based investment firm Lochpine Capital will invest a combined 20% worth about $28 million to produce battery-grade graphite using forestry byproducts, according to an investor presentation.CATL and CarbonScape will test the technology at CATL's facilities in China.

HKG:3750SHE:300750
Asia

Xunce Technology Explores Data Tokenization Partnership With Gechuang Dongzhi

Xunce Technology (HKG:3317) is exploring a partnership with Gechuang Dongzhi (Shenzhen) Technology focused on data tokenization, according to a Sunday filing with the Hong Kong bourse.Under the memorandum of understanding, the companies will collaborate on the standardization and assetization of industrial data.The firms will also jointly develop industrial AI agents and explore the business models of industrial data assetization and token-based billing.

HKG:3317